Overview
- The peer‑reviewed study, published Feb. 11 in Science Translational Medicine, identifies Aβ42 buildup inside presynaptic synaptic vesicles as an early event in Alzheimer’s.
- Across mouse models, cultured human neurons, and Down syndrome brain tissue, levetiracetam prevented neurons from forming Aβ42.
- Mechanistically, the drug’s binding to SV2A slows vesicle recycling, increases APP at the cell surface, and steers processing away from the amyloidogenic pathway.
- A correlative analysis of National Alzheimer’s Coordinating Center data linked levetiracetam use with a modestly longer interval from cognitive decline to death, though it does not establish causation.
- Investigators caution that benefit would likely require very early use in high‑risk groups and note the drug’s short half‑life, prompting work on longer‑lasting SV2A‑targeting analogs and targeted trials.